Cryptocurrency NEAR Protocol’s Price Increased More Than 3% Within 24 hours

NEAR Protocol's (CRYPTO: NEAR) price has increased 3.19% over the past 24 hours to $1.61, which is in the opposite direction of its trend over the past week, where it has experienced a 1.0% loss, moving from $1.61 to its current price.

NEAR Protocol’s (CRYPTO: NEAR) price has increased 3.19% over the past 24 hours to $1.61, which is in the opposite direction of its trend over the past week, where it has experienced a 1.0% loss, moving from $1.61 to its current price. As it stands right now, the coin’s all-time high is $20.44.

The chart below compares the price movement and volatility for NEAR Protocol over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.

price_chart

The trading volume for the coin has tumbled 64.0% over the past week along with the circulating supply of the coin, which has fallen 0.22%. This brings the circulating supply to 831.76 million, which makes up an estimated 83.18% of its max supply of 1.00 billion. According to our data, the current market cap ranking for NEAR is #36 at $1.34 billion.

supply_and_vol

Powered by CoinGecko API

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Asia Mixed, European Indexes Slide; Crude Trades Under $78 – Global Markets Today While US Slept

Asian markets showed mixed results on Friday, with Japan's Nikkei 225 and Australia's S&P/ASX 200 closing higher, while China's indices and Hong Kong's Hang Seng ended lower. Despite a rise in Tokyo's core CPI inflation, it remains below the Bank of Japan's target, raising questions about future interest rate hikes.

ADIV

Read More

What’s Going On With Candel Therapeutics Stock?

Candel Therapeutics, Inc. (NASDAQ:CADL) shares are trading higher Thursday after the company received FDA orphan drug designation for CAN-2409 for the treatment of pancreatic cancer. "We recently reported data from the phase 2 randomized clinical trial of CAN-2409 in borderline resectable pancreatic cancer, showing that CAN-2409, when added to standard of care, more than doubled the median overall survival obtained with standard of care alone," said Paul Peter Tak, MD, PhD, CEO of Candel.

CADL